Victory Capital Management
AMLX icon

Victory Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Victory Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
10,644
+92
+0.9% +$1.29K ﹤0.01% 2235
2025
Q4 		$127K Buy
+10,552
New +$143K ﹤0.01% 2254
2024
Q2 		– Sell
-13,514
Closed -$38.4K – 2475
2024
Q1 		$38.4K Buy
+13,514
New +$177K ﹤0.01% 2396

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Victory Capital Management's AMLX Position: Q1 2026 in Review

Victory Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 0.87% in Q1 2026, buying an estimated $1.29K and bringing the position to 10,644 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

Victory Capital Management first reported a position in AMLX in Q1 2024 and has held it in 3 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Victory Capital Management held 10,644 shares of Amylyx Pharmaceuticals worth $148K as of Q1 2026.
  • Victory Capital Management bought 92 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.29K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2235 holding.
  • Victory Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.